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Abstract
Background and objectives: Malignant hyperthermia (MH) is a pharmacogenetic skeletal muscle 
disorder characterized by a hypermetabolic state after anesthesia with succinylcholine and/
or volatile anesthetics. Various neuromuscular syndromes are associated with susceptibility; 
however, Moebius syndrome has not been reported. Dantrolene is the drug of choice for treatment. 
Recurrence may occur in up to 20% of cases after the initial event treatment.
Case Report: Male infant, ﬁ rst twin, 7 months old, weighing 6.5 kg and presenting with Moebius 
syndrome was admitted for clubfoot repair. The patient had MH after exposure to sevoﬂ urane 
and succinylcholine, which was readily reversed with dantrolene maintained for 24 hours. Ten 
hours after dantrolene discontinuation, there was recrudescence of MH that did not respond 
satisfactorily to treatment, and the patient died.
Discussion: Musculoskeletal disorders in children are associated with increased risk of developing 
MH, although Moebius syndrome has not yet been reported. Dantrolene is the drug of choice for 
treating this syndrome; prophylaxis is indicated during the ﬁ rst 24-48 hours of the episode onset. 
The main risk factors for recurrence are muscular type, long latency after anesthetic exposure, 
and increased temperature. The child had only one risk factor. This case leads us to reﬂ ect on 
how we must be attentive to children with musculoskeletal disease and maintain treatment for 
48 hours.
© 2013 Sociedade Brasileira de Anestesiologia. Published by Elsevier Editora Ltda. 
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Introduction
Malignant hyperthermia (MH) is a hereditary pharmacogene-
tic skeletal muscle disorder  characterized by a hyperme-
tabolic state after anesthesia with succinylcholine and/or 
volatile anesthetics 1-3. 
The initial diagnosis is clinical, mainly characterized by 
tachycardia and increased end-tidal carbon dioxide. In the 
late phase, there is rapid increase in body temperature and 
extreme acidosis, marked by loss of intracellular calcium ion 
levels and uncontrolled increase in skeletal muscle metabo-
lism, which may progress to severe rhabdomyolysis 4. 
In the 1980s, the caffeine-halothane contracture test 
became the gold standard diagnostic test for MH and a variety 
of neuromuscular disorders associated with susceptibility 
to this syndrome. Duchenne muscular dystrophy, congenital 
myotonia, myotonic dystrophy, nonspeciﬁ c myopathies, 
central core disease, King Denborough syndrome, osteo-
genesis imperfecta, and Schwartz-Jampel syndrome were 
reported 5. 
Incidence and prevalence of MH are variable, with no 
difference regarding gender or ethnicity. The incidence varies 
with age: approximately 1:50,000 in adults and 1:15,000 in 
children 6-10.
The pathophysiological mechanism is associated with 
ryanodine receptor type-1 (RYR1) mutation, which is respon-
sible for calcium release from the sarcoplasmic reticulum. 
Mutation in RYR1 is found in approximately 50% of the sus-
ceptible families 11-13. 
The occurrence of MH is seen in the ﬁ rst or in subsequent 
exposures to halogenated agents 14,15.
Currently, dantrolene remains the primary basis for the 
successful management of MH 16,17.
The syndrome recrudescence may occur in up to 20% 
of cases, mostly within 16 hours of the clinical condition 
onset 18.
Moebius syndrome is a rare disorder, characterized by 
unilateral or bilateral facial paralysis and extraocular mo-
vements defects, secondary to congenital paralysis of the 
facial (VII) and abducens (VI) nerves 19,20. It is followed by 
other cranial nerve dysfunctions, orofacial abnormalities, 
musculoskeletal hypotonia, and orthopedic anomalies, in-
cluding clubfoot 21.
To date, there is no report in literature on the association 
between Moebius syndrome and malignant hyperthermia. 
The aim of this study was to report a case of malignant 
hyperthermia in an infant with Moebius syndrome, as well 
as its management and outcome.
Case Report
Male infant, ﬁ rst twin, 7 months old, weighing 6.5 kg, pre-
senting a history of prematurity (born at 34 weeks gestation) 
and Moebius syndrome. He was admitted for surgical repair 
of clubfoot and showed development consistent with his age. 
Laboratory tests were normal. The patient did not undergo 
prior surgery, and there were no reports of complications with 
general anesthesia in the family. On arrival to the operating 
room, the patient was monitored with ECG, pulse oximetry, 
and noninvasive blood pressure. After preoxygenation for 
5 minutes, inhalational induction with sevoﬂ urane 3% was 
started, followed by venoclysis. Soon after exposure to the 
halogenated anesthetic agent, the infant had hypertonia and 
agitation, which was interpreted as absence of anesthetic 
plan. For management, the concentration of sevoﬂ urane 
was increased to 8%, followed by administration of atropine 
(20 mcg.kg-1) and muscle relaxation with succinylcholine 
(1 mg.kg-1), resulting in additional hypertonia, generalized 
muscle contraction including masseter muscle, which pre-
vented tracheal intubation and impaired the ventilation 
by mask, with consequent desaturation. The hypothesis 
of MH was suggested, sevoﬂ urane was discontinued, and 
rocuronium (1 mg.kg-1) was administered in order to facili-
tate tracheal intubation. The child was intubated and the 
surgery canceled. The patient was monitored with PETCO2, 
axillary temperature, and blood pressure measurements. In 
the ﬁ rst 10 minutes after exposure to the triggering agents, 
there was a progressive increase of PETCO2 (levels near 80 
mm Hg), despite hyperventilation; tachycardia (rate of 150 
bpm, evolving to 180 bpm); hypertension (120/80 mm Hg), 
even with the use of midazolam (0.1 mg.kg-1). After 20 mi-
nutes of the event occurrence, hyperthermia (T = 38°C) was 
observed. Laboratory tests were performed (arterial blood 
gases and electrolytes), and general and speciﬁ c measures 
for MH were established.
Ringer lactate was administered with 1% glucose (20 
mL.kg-1) and cooling performed with physical means (air-
cooling system, cold pads, and cold serum). The patient 
was hyperventilated with O2 (100%), reducing PETCO2 to 
45 mm Hg. After measurement of arterial blood gases and 
electrolytes (Table 1), mixed metabolic acidosis associated 
with hyperkalemia was diagnosed, and NaHCO3 8.4% (1 mEq.
kg-1), calcium gluconate 10% (20 mg.kg-1), and bolus of Ringer 
lactate (20 mL.kg-1) were administered. Speciﬁ c treatment 
for MH was performed with dantrolene (2.5 mg.kg-1), which 
occurred approximately 60 minutes after the onset of signs 
and symptoms. 
Overall condition improvement was observed after dan-
trolene administration. The intubated and sedated infant 
was taken to the Intensive Care Unit (ICU). Dantrolene was 
prescribed at doses of 1 mg.kg-1 every 6h. Laboratory tests 
as response curve were performed to assess the degree 
of muscle destruction, blood gas, and electrolytes (Table 
2). ICU baseline clinical parameters were satisfactory. 
Hyperthermia, tachycardia, hypertension or desaturation 
were not observed.
The patient developed respiratory failure, with SatO2 
up to 80%, despite FiO2 of 100%, proper ventilation, and no 
changes in chest X-ray. New laboratory tests (Table 3) were 
Table 1 Arterial blood gases and electrolytes.
Blood gas Electrolytes
pH 7.17 Na+ 139.7 mEq.L-1
pCO2 55.7 mmHg K+ 5.1 mEq.L
-1
pO2 297 mmHg Blood glucose 334 mg.dL
-1
SatO2 99%   
HCO3
- std 17.4 mEq.L-1   
BE (-8.6)   
BE: Base Excess.
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performed and arterial blood gases showed signiﬁ cant respi-
ratory acidosis, hyperkalemia, and hyperglycemia. He evolved 
with cardiac arrhythmias (extrasystoles), desaturation, and 
bradycardia with cardiopulmonary arrest (CA). CA protocol 
was applied and dantrolene (1 mg.kg-1) reintroduced, without 
success, and the patient died due to asystolic CA.
Discussion
MH is a potentially fatal medical condition. The Clinical 
Grading Scale criteria to predict MH are: respiratory acidosis 
characterized by end-tidal CO2 (ETCO2 > 55 mm Hg); PaCO2 > 
60 mm Hg observed in arterial blood gas; unexplained cardiac 
manifestation characterized by sinus tachycardia, ventricular 
tachycardia or ventricular ﬁ brillation; metabolic acidosis with 
a base deﬁ cit > 8 mEq.L-1; pH < 7.25; generalized muscle 
rigidity; severe masseter muscle rigidity; muscle lysis repre-
sented by serum creatine phosphokinase (CPK > 20,000 U.L-1); 
dark urine; increased myoglobin levels in plasma or urine; 
plasma potassium > 6 mEq.L-1; rapid rise of temperature; 
temperature > 38.8°C; rapid reversal of MH signs with dan-
trolene administration; elevated serum concentration of 
creatine phosphokinase at rest; family history consistent with 
autosomal dominant inheritance 22. The case presented here 
had the classical clinical diagnostic criteria for MH.
In an American study assessing 286 cases of MH between 
1987 and 2006, it was found that the most frequently manifes-
ted clinical signs were: hypercarbia (92.2%), sinus tachycardia 
(72.9%), rapid increase in core body temperature (64.7%), 
generalized muscle rigidity (40.8%), masseter spasm (26.7%), 
and sweating (17.6%) 23. This clinical signs were present in 
the infant in question.
The main point of the management and treatment of an 
acute crisis is the immediate discontinuation of the triggering 
agent, followed by hyperventilation associated with adminis-
tration of dantrolene (2.5 mg.kg-1), which can be repeated 
until the MH crisis is aborted. The suggested dose limit of 
dandrolene is 10 mg.kg-1, which may be increased depen-
ding on the case. Cooling measures should be started and 
arrhythmias treated; do not use calcium channel blockers; 
perform blood tests (blood gas, electrolytes, creatine phos-
phokinase, myoglobin plasma and urine, coagulation proﬁ le 
should be checked every 6 to 12 hours); hyperkalemia should 
be treated when indicated; continue dantrolene at a dose of 
1 mg.kg-1 every 4 to 8 hours for 24 to 48 hours. The desired 
urine output is 2 mL.kg.min-1, which can be stimulated with 
mannitol, furosemide and ﬂ uids, if necessary; assess the need 
for invasive monitoring and mechanical ventilation; observe 
the patient in the ICU for at least 36 hours. It is recommen-
ded to refer the patient and family to an MH testing center 
for contracture or DNA test. Patients affected by MH  must 
receive dantrolene and be closely monitored for 48 to 72 
hours, as even with dantrolene treatment, 20% of patients 
may experience recrudescence of the symptoms 18,22. 
In the case described here, all recommendations were 
followed. Dantrolene was administered every 6 hours during 
the 24 hours following the initial episode, as recommended 
in the literature, but recrudescence occurred 10 hours after 
drug treatment discontinuation.
Laboratory evaluation after the event should include 
testing for disseminated intravascular coagulation (DIC), as 
well as the observation of myoglobinuria and renal function. 
DIC is more frequent when the body temperature exceeds 
41°C 22. In the case described, muscle lysis was not intense, 
as seen on the initial tests, and there was no myoglobinuria, 
probably because treatment was started early.
Currently, dantrolene is the only treatment speciﬁ c for 
MH. Because this syndrome present with nonspeciﬁ c signs 
and treatment delay results in life-threatening outcome, 
this drug should be administered as soon as MH is suspected. 
However, dantrolene does not come without its complications 
- hepatotoxicity is one of its potential adverse effects 15,24. In 
an analysis of 368 patients who received dantrolene for MH 
treatment, the most frequent complications were muscle 
Table 2 Laboratory tests – response curve during 
Intensive Care (ICU) stay.
Tests ICU Admission 24 h after ICU admission
pH 7.37 7.4
pO2 135 mm Hg 132.8 mm Hg
pCO2 45.1 mm Hg 40 mm Hg
HCO3
- 25.5 mg.dL-1 24 mg.dL-1
SatO2 98% 98%
Na+ 136 mEq.L-1 136 mEq.L-1
K+ 5.1 mEq.L-1 3.17 mEq.L-1
Ca++ 9.6 mg.dL-1  
GOT 78 U.L-1 50 U.L-1
GPT 23 U U.L-1 25 U.L-1
LDH 1691 U.L-1  
ALP 452 U.L-1  
CPK 524 U.L-1 323 U.L-1
Glicemia 524 mg.dL-1 118 mg.dL-1
GOT: Glutamic oxaloacetic transaminase; GPT: Glutamic 
pyruvic transaminase; ALP: Alkaline phosphatase; CPK: creatine 
phosphokinase; LDH: Lactate dehydrogenase.
Table 3 Evolution of arterial blood gases and 
electrolytes.
Arterial 
blood gas Electrolytes
pH 6,8 Na+ 122 mEq.L-1
pCO2 91 mm Hg K+ 6.6 mEq.L
-1
pO2 113 mm Hg Blood Glucose 425 mg.dL
-1
SatO2 99%   
HCO3
- std 31 mEq.L-1   
BE (-) 6   
BE: Base Excess.
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weakness (21.7%), phlebitis (9%), gastrointestinal discomfort 
(4.1%), and respiratory failure (3.8 %) 25. There are reports of 
apnea in newborns and infants after using this drug 26,27. 
Due to the potential toxicity of dantrolene and its respira-
tory depression effect on infants, in addition to complications 
associated with prolonged mechanical ventilation 28, dantrolene 
discontinuation was decided after 24 hours. Unfortunately, 
the syndrome recrudescence occurred 10 hours after treat-
ment discontinuation.
Recrudescence is deﬁ ned as the development of MH signs 
2 hours after the initial episode treatment. Recrudescence 
clinical signs include increased heart rate, minute ventila-
tion to maintain PaCO2, and temperature. In a case-control 
study, data from 308 patients with HM were collected, 63 
in the recrudescent group and 245 in the control group. 
Recrudescence occurred between 2.5 and 72 hours after 
the MH episode, with 80% occurring at the ﬁ rst 16 hours. 
The three main factors associated with recrudescence were 
muscular type, HM episode long latency after induction of 
anesthesia, and increased temperature 18. The infant in the 
case reported here had only one risk factor for recrudescence 
(increased temperature at the time of the initial episode), 
which occurred 36 hours after the initial episode and 10 hours 
after discontinuation of treatment with dantrolene.
Because MH has a strong genetic character, and the pa-
tient reported here was a monochorionic twin, contracture 
test in the other twin would be extremely beneﬁ cial in 
diagnosing the syndrome. However, the non-recommendation 
of this diagnostic test in children weighing less than 20 kg 
prevents its realization 29. Thus, clarifying and counseling the 
family were adopted as a means of preventing morbidity in 
the other twin. 
In a study assessing quantitatively the existence of comor-
bidities and MH diagnosis, it was found that compared with 
the general pediatric population, children diagnosed with 
MH had signiﬁ cant comorbidities, such as musculoskeletal 
system and connective tissue diseases, circulatory system di-
seases, and congenital anomalies. The speciﬁ c diagnosis most 
strongly associated with MH was muscular dystrophy 30. The 
child described here had a musculoskeletal syndrome, which 
corroborates the ﬁ ndings of the above-mentioned study.
After consideration on the case, we understand that close 
attention should be paid to children with comorbid condi-
tions, particularly musculoskeletal syndromes and muscular 
dystrophies. We understand the importance of dantrolene 
administration for a time exceeding 24 hours; the need for a 
better understanding of this syndrome by anesthesiologists, 
intensive care team, and other professionals; and that the 
possibility of MH recrudescence should always be considered. 
Moreover, the availability of dantrolene in all hospitals is es-
sential for managing cases, as well as research development 
for new drugs speciﬁ c for MH, such as azumolene, possibly 
less toxic 31.
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